Skip To Content

Vitalant Statement on Emergency Use Authorization of Convalescent Plasma

Aug. 24, 2020 – The following statement regarding the FDA’s EUA for convalescent plasma can be attributed to Vitalant’s Donor Services Senior Vice President and Chief of Marketing Cliff Numark:

“Vitalant began collecting convalescent plasma in April 2020 and we are pleased to continue to provide this plasma as a potentially lifesaving treatment for individuals battling COVID-19 during the Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA). To date, Vitalant donors have contributed more than 24,000 convalescent plasma units—offering hope for patients and their families.

Volunteer donors are the most important factor in our ability to help patients. Vitalant is testing all blood and platelet donations for COVID-19 antibodies to help identify donors who might be able to give convalescent plasma. Additionally, individuals who have recovered from COVID-19 are urged to register to donate plasma by calling 866-CV-PLSMA (866-287-5762).

The FDA’s EUA allows for greater access to the treatment and sets additional standards for use, which Vitalant supports. Vitalant also strongly supports randomized clinical trials to fully understand the benefits as this pandemic continues.

Vitalant was already increasing convalescent plasma donor outreach efforts to meet growing demand. Now, with the FDA’s EUA, we will continue these efforts with additional urgency.”